BRNS (Barinthus Biotherapeutics) Deferred Policy Acquisition Costs


BRNS Barinthus Biotherapeutics PLC BRNS
52 GF Score
Price $0.69
GF Value $1.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.

BRNS
52GF Score
Barinthus Biotherapeutics PLC BRNS
Deferred Policy Acquisition Costs is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of $0.69 is trading 38.2% below its estimated GF Value™ of $1.12. GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.

Key valuation signals for BRNS:

  • Deferred Policy Acquisition Costs:
  • GF Value™: $1.12 vs. price of $0.69 (38.2% below fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
52GF Score

Get the complete analysis for BRNS

Deferred Policy Acquisition Costs is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.69
Price
$1.12
GF Value